FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010969626> ?p ?o ?g. }

• W3010969626 endingPage "L920" @default.
• W3010969626 startingPage "L908" @default.
• W3010969626 abstract "Over 2,000 mutations have been reported in the cystic fibrosis transmembrane conductance regulator ( cftr) gene, many of which cause disease but are rare and have no effective treatment. Thus, there is an unmet need for new, mutation-agnostic therapies for cystic fibrosis (CF). Phosphodiesterase (PDE) inhibitors are one such class of therapeutics that have been shown to elevate intracellular cAMP levels and stimulate CFTR-dependent anion secretion in human airway epithelia; however, the number of people with CF that could be helped by PDE inhibitors remains to be determined. Here we used Fisher rat thyroid (FRT) cells stably transduced with rare human CFTR mutants and studied their responsiveness to the dual phosphodiesterase 3/4 inhibitor RPL554 (Verona Pharma). Through its inhibitory effect on PDE4D, we find that RPL554 can elevate intracellular cAMP leading to a potentiation of forskolin-stimulated current mediated by R334W, T338I, G551D, and S549R mutants of CFTR when used alone or in combination with CFTR modulators. We also were able to reproduce these effects of RPL554 on G551D-CFTR when it was expressed in primary human bronchial epithelial cells, indicating that RPL554 would have stimulatory effects on rare CFTR mutants in human airways and validating FRT cells as a model for PDE inhibitor studies. Furthermore, we provide biochemical evidence that VX-809 causes surprisingly robust correction of several class III and IV CFTR mutants. Together, our findings further support the therapeutic potential of RPL554 for patients with CF with class III/IV mutations and emphasize the potential of PDEs as potential drug targets that could benefit patients with CF." @default.
• W3010969626 created "2020-03-23" @default.
• W3010969626 creator A5004357421 @default.
• W3010969626 creator A5011157592 @default.
• W3010969626 creator A5045887929 @default.
• W3010969626 creator A5056371233 @default.
• W3010969626 date "2020-05-01" @default.
• W3010969626 modified "2023-10-17" @default.
• W3010969626 title "The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants" @default.
• W3010969626 cites W1494978858 @default.
• W3010969626 cites W1567281461 @default.
• W3010969626 cites W1589654967 @default.
• W3010969626 cites W1959359615 @default.
• W3010969626 cites W1972029787 @default.
• W3010969626 cites W1975572445 @default.
• W3010969626 cites W1982071077 @default.
• W3010969626 cites W1982108210 @default.
• W3010969626 cites W1988790251 @default.
• W3010969626 cites W1989180635 @default.
• W3010969626 cites W2003428468 @default.
• W3010969626 cites W2004155358 @default.
• W3010969626 cites W2010211613 @default.
• W3010969626 cites W2031854098 @default.
• W3010969626 cites W2035131077 @default.
• W3010969626 cites W2039462910 @default.
• W3010969626 cites W2039599894 @default.
• W3010969626 cites W2049374415 @default.
• W3010969626 cites W2050573110 @default.
• W3010969626 cites W2052588826 @default.
• W3010969626 cites W2071407356 @default.
• W3010969626 cites W2082968284 @default.
• W3010969626 cites W2089006464 @default.
• W3010969626 cites W2090601537 @default.
• W3010969626 cites W2115127888 @default.
• W3010969626 cites W2115793628 @default.
• W3010969626 cites W2121200653 @default.
• W3010969626 cites W2127920211 @default.
• W3010969626 cites W2132756075 @default.
• W3010969626 cites W2135141635 @default.
• W3010969626 cites W2137255331 @default.
• W3010969626 cites W2151631634 @default.
• W3010969626 cites W2332031191 @default.
• W3010969626 cites W2336230469 @default.
• W3010969626 cites W2337762305 @default.
• W3010969626 cites W2411751971 @default.
• W3010969626 cites W2462076110 @default.
• W3010969626 cites W2463363973 @default.
• W3010969626 cites W2528316681 @default.
• W3010969626 cites W2884228015 @default.
• W3010969626 cites W2897626245 @default.
• W3010969626 cites W2908796392 @default.
• W3010969626 cites W2917538474 @default.
• W3010969626 cites W2951581523 @default.
• W3010969626 cites W2953112077 @default.
• W3010969626 cites W4241884576 @default.
• W3010969626 doi "https://doi.org/10.1152/ajplung.00285.2019" @default.
• W3010969626 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32159371" @default.
• W3010969626 hasPublicationYear "2020" @default.
• W3010969626 type Work @default.
• W3010969626 sameAs 3010969626 @default.
• W3010969626 citedByCount "10" @default.
• W3010969626 countsByYear W30109696262020 @default.
• W3010969626 countsByYear W30109696262021 @default.
• W3010969626 countsByYear W30109696262022 @default.
• W3010969626 countsByYear W30109696262023 @default.
• W3010969626 crossrefType "journal-article" @default.
• W3010969626 hasAuthorship W3010969626A5004357421 @default.
• W3010969626 hasAuthorship W3010969626A5011157592 @default.
• W3010969626 hasAuthorship W3010969626A5045887929 @default.
• W3010969626 hasAuthorship W3010969626A5056371233 @default.
• W3010969626 hasConcept C104317684 @default.
• W3010969626 hasConcept C126322002 @default.
• W3010969626 hasConcept C134018914 @default.
• W3010969626 hasConcept C143065580 @default.
• W3010969626 hasConcept C181199279 @default.
• W3010969626 hasConcept C185592680 @default.
• W3010969626 hasConcept C24998067 @default.
• W3010969626 hasConcept C2776766087 @default.
• W3010969626 hasConcept C2776938444 @default.
• W3010969626 hasConcept C2778428886 @default.
• W3010969626 hasConcept C2779276759 @default.
• W3010969626 hasConcept C501734568 @default.
• W3010969626 hasConcept C55493867 @default.
• W3010969626 hasConcept C62826618 @default.
• W3010969626 hasConcept C71924100 @default.
• W3010969626 hasConcept C79879829 @default.
• W3010969626 hasConcept C86803240 @default.
• W3010969626 hasConcept C95444343 @default.
• W3010969626 hasConcept C98274493 @default.
• W3010969626 hasConceptScore W3010969626C104317684 @default.
• W3010969626 hasConceptScore W3010969626C126322002 @default.
• W3010969626 hasConceptScore W3010969626C134018914 @default.
• W3010969626 hasConceptScore W3010969626C143065580 @default.
• W3010969626 hasConceptScore W3010969626C181199279 @default.
• W3010969626 hasConceptScore W3010969626C185592680 @default.
• W3010969626 hasConceptScore W3010969626C24998067 @default.
• W3010969626 hasConceptScore W3010969626C2776766087 @default.
• W3010969626 hasConceptScore W3010969626C2776938444 @default.

• next